Canton Strategic Holdings CNTN
NASDAQ CNTN
$2.28 +0.03 (+1.33%)
As of: Sep 4, 2026 · 3:59 PM EDT

Canton Strategic Holdings (CNTN) Research & Development (2021 - 2026)

Canton Strategic Holdings' (CNTN) quarterly Research & Development came in at $267823.0 in Q1 2026, down 54.92% YoY from $594070.0 in Q1 2025, and down 83.83% on a QoQ basis from $1.7 million in Q4 2025.

Analysis

Canton Strategic Holdings (CNTN) Research & Development (2021 - 2026) Analysis & Trends

Canton Strategic Holdings (CNTN) has 6 years of Research & Development data on file, last reported at $267823.0 in Q1 2026.

  • Quarterly Research & Development fell 54.92% year-over-year to $267823.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (down 53.9% YoY) and the FY2025 annual result came in at $3.1 million, down 51.91% from the prior year.
  • Research & Development declined to $267823.0 in Q1 2026, from $1.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.3 million in Q3 2024 to a low of $267823.0 in Q1 2026.
  • A 5-year average of $915996.6 and a median of $831844.0 in 2022 frame the typical range for Research & Development.
  • Annual changes were most pronounced in 2022 — Research & Development soared 1766.15% — and 2025, when it sank 87.83%.
  • Tracing CNTN's Research & Development over 5 years: stood at $683205.0 in 2022, then soared by 45.3% to $992725.0 in 2023, then jumped by 110.07% to $2.1 million in 2024, then declined by 20.6% to $1.7 million in 2025, then slumped by 83.83% to $267823.0 in 2026.
  • The last three Research & Development figures came in at $267823.0 (Q1 2026), $1.7 million (Q4 2025), and $277803.0 (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 993.80 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.63 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -486.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 651.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 394.92 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 612.28 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 413.13 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 97.90 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 210.03 Mn
10 Canton Strategic Holdings 493.37 Mn 493.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 267,823.00
Dec 31, 2025 1.66 Mn
Sep 30, 2025 277,803.00
Jun 30, 2025 123,638.00
Mar 31, 2025 594,070.00
Dec 31, 2024 2.09 Mn
Sep 30, 2024 2.28 Mn
Jun 30, 2024 999,553.00
Mar 31, 2024 1.03 Mn
Dec 31, 2023 992,725.00
Sep 30, 2023 488,177.00
Jun 30, 2023 1.03 Mn
Mar 31, 2023 1.05 Mn
Dec 31, 2022 683,205.00
Sep 30, 2022 831,844.00
Jun 30, 2022 455,546.00
Mar 31, 2022 307,829.00
Dec 31, 2021 -41,005.00
Sep 30, 2021 313,133.00
Jun 30, 2021 674,765.00